MetaVia (NASDAQ: MTVA) logs $9.1M loss and faces going-concern risk
Rhea-AI Filing Summary
MetaVia Inc., a clinical-stage biotech focused on cardiometabolic diseases, reported a net loss of $5.3 million for the quarter and $9.1 million for the six months ended June 30, 2026, driven by $9.4 million in combined research and development and general and administrative expenses.
Cash and cash equivalents were $12.6 million at June 30, 2026, up from $10.3 million at year-end, helped by a January 2026 underwritten equity offering, at-the-market sales, and warrant exercises that together provided $10.4 million of financing in the first half.
MetaVia highlights that its recurring losses, negative operating cash flows and limited cash raise substantial doubt about its ability to continue as a going concern within one year without additional capital. The company continues Phase 2a development of vanoglipel for MASH and Phase 1 trials of DA-1726 for obesity, with key data readouts planned in the fourth quarter of 2026.
Positive
- None.
Negative
- Going-concern uncertainty: With $12.6 million in cash, a first-half net loss of $9.1 million, and ongoing negative operating cash flows, MetaVia states that these conditions raise substantial doubt about its ability to continue as a going concern within one year without additional financing.
Filing Explained
Existing holders face a larger potential share base: 8.96 million warrants remain outstanding, while the ATM ceiling was raised to $4 million.
MetaVia’s unaudited Form 10-Q reports the company’s position through
The January financing’s 1,998,704 pre-funded warrants were exercised during the first half, while 4,478,322 Series C and 3,758,822 Series D warrants remained outstanding at quarter-end; the Series D warrants are callable only after specified positive DA-1726 data and other conditions.
The company had sold 422,919 ATM shares by quarter-end, with
A named near-term obligation is the
Key Figures
Key Terms
metabolic dysfunction-associated steatohepatitis medical
at the market offering financial
pre-funded warrants financial
going concern financial
beneficial ownership limitation regulatory
Phase 1 clinical trial medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What were MetaVia (MTVA)'s net losses for Q2 and the first half of 2026?
How much cash did MetaVia (MTVA) have as of June 30, 2026?
Does MetaVia (MTVA) face a going-concern risk?
What are MetaVia (MTVA)'s main drug development programs?
How is MetaVia (MTVA) funding its operations in 2026?
What were MetaVia (MTVA)'s research and development expenses in the first half of 2026?
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
Form
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | |
6
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | |
Commission file number
(Exact name of Registrant as specified in its charter)
(State or other jurisdiction of incorporation or organization) | (IRS Employer Identification No.) | |
(Address of principal executive offices) | (Zip Code) |
(
(Registrant’s telephone number, including area code)
Not applicable
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class | Trading Symbol(s) | Name of Each Exchange On Which Registered | ||
The |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ◻ | Accelerated filer ◻ |
Smaller reporting company | |
Emerging growth company |
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes
As of August 3, 2026, the registrant had
Table of Contents
METAVIA INC.
Table of Contents
Special Note Regarding Forward-Looking Statements | 2 | |
Part I | Financial Information | 3 |
Item 1. | Financial Statements (Unaudited) | 3 |
Condensed Consolidated Balance Sheets as of June 30, 2026 and December 31, 2025 (Unaudited) | 3 | |
Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2026 and 2025 (Unaudited) | 4 | |
Condensed Consolidated Statements of Changes in Stockholders’ Equity for the three and six months ended June 30, 2026 and 2025 (Unaudited) | 5 | |
Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2026 and 2025 (Unaudited) | 6 | |
Notes to the Condensed Consolidated Financial Statements (Unaudited) | 7 | |
Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 18 |
Item 3. | Quantitative and Qualitative Disclosures about Market Risk | 25 |
Item 4. | Controls and Procedures | 25 |
Part II | Other Information | 26 |
Item 1. | Legal Proceedings | 26 |
Item 1A. | Risk Factors | 26 |
Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 26 |
Item 3. | Defaults Upon Senior Securities | 26 |
Item 4. | Mine Safety Disclosures | 26 |
Item 5. | Other Information | 26 |
Item 6. | Exhibits | 26 |
Signatures | 28 | |
1
Table of Contents
Unless the context requires otherwise, references in this Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026 (this “Report”) to “we,” “us,” “the Company,” “MetaVia,” “the Registrant” and “our” refer to MetaVia Inc. and its subsidiaries.
Special Note Regarding Forward-Looking Statements
This Report contains “forward-looking statements” within the meaning of the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements that address future operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation, our expectations regarding our ability to execute our commercial strategy; our expectations regarding the sufficiency of our existing cash and cash equivalents on hand to fund our operations; the timeline for regulatory submissions, regulatory steps and potential regulatory approval of our current and future product candidates; the ability to realize the benefits of the license agreement with Dong-A ST Co., Ltd., a related party (“Dong-A ST”), including the impact on our future financial and operating results; the ability to integrate the product candidates into our business in a timely and cost-efficient manner; the cooperation of our contract manufacturers, clinical study partners and others involved in the development of our current and future product candidates; our ability to initiate clinical trials on a timely basis; our planned clinical trials and our ability to recruit subjects for our clinical trials; the costs related to the license agreement, known and unknown, including costs of any litigation or regulatory actions relating to the license agreement; the changes in applicable laws or regulations; and the effects of changes to our stock price on the terms of the license agreement and any future fundraising and other risks and uncertainties described in this Report and in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (“2025 Form 10-K”), and in our other filings with the Securities and Exchange Commission (the “SEC”).
Forward-looking statements are based on management’s current expectations and assumptions about future events, which are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict. These statements may be identified by words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. In addition, statements that “we believe,” “we expect,” “we anticipate” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Report and management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on forward-looking statements because they speak only as of the date when made. We undertake no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results or expectations, except as required by law.
Forward-looking statements are subject to a number of risks and uncertainties, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements, including without limitation, the possibility that regulatory authorities do not accept our applications or approve the marketing of our products, the possibility we may be unable to raise the funds necessary for the development and commercialization of our products, and those described in this Report and in our other filings with the SEC.
We operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for us to predict all risk factors and uncertainties. We qualify all of our forward-looking statements by these cautionary statements.
2
Table of Contents
Part I - Financial Information
Item 1.Financial Statements
MetaVia Inc.
Condensed Consolidated Balance Sheets
(Unaudited - In thousands, except share and per share amounts)
As of | ||||||
June 30, 2026 | December 31, 2025 | |||||
Assets | ||||||
Current assets | ||||||
Cash and cash equivalents | $ | | $ | | ||
Prepaid expenses and other current assets | | | ||||
Total current assets |
| |
| | ||
Property and equipment, net |
| |
| | ||
Right-of-use asset | | | ||||
Other assets | | | ||||
Total assets | $ | | $ | | ||
Liabilities and stockholders’ equity | ||||||
Current liabilities | ||||||
Accounts payable | $ | | $ | | ||
Clinical trial accrued liabilities | | | ||||
Accrued expenses and other current liabilities |
| |
| | ||
Warrant liabilities | | | ||||
| | |||||
Lease liability, short-term | | | ||||
Total current liabilities |
| |
| | ||
Lease liability, long-term | | | ||||
Total liabilities |
| |
| | ||
Commitments and contingencies (Note 6) | ||||||
Stockholders’ equity | ||||||
Preferred stock, $ | ||||||
Common stock, $ |
| |
| | ||
Additional paid–in capital |
| |
| | ||
Accumulated deficit |
| ( |
| ( | ||
Total stockholders’ equity |
| |
| | ||
Total liabilities and stockholders’ equity | $ | | $ | | ||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
3
Table of Contents
MetaVia Inc.
Condensed Consolidated Statements of Operations
(Unaudited - In thousands, except share and per share amounts)
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||
2026 | 2025 | 2026 | 2025 | |||||||||
Operating expenses | | | | | ||||||||
Research and development | $ | | $ | | $ | | $ | | ||||
General and administrative | | | | | ||||||||
Total operating expenses |
| |
| |
| |
| | ||||
Loss from operations |
| ( |
| ( |
| ( |
| ( | ||||
Other income (expense) | ||||||||||||
(Loss) gain from change in fair value of warrant liabilities | ( | | | | ||||||||
Interest income, net | | | | | ||||||||
Total other income | | | | | ||||||||
Loss before income taxes | ( | ( | ( | ( | ||||||||
Provision for income taxes | |
| | |
| | ||||||
Net loss |
| ( |
| ( |
| ( |
| ( | ||||
Loss per share of common stock, basic and diluted | $ | ( | $ | ( | $ | ( | $ | ( | ||||
Weighted average shares of common stock, basic and diluted |
| | |
| | | ||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
4
Table of Contents
MetaVia Inc.
Condensed Consolidated Statements of Changes in Stockholders’ Equity
(Unaudited - In thousands, except share amounts)
Additional | ||||||||||||||
Common Stock | Paid-In | Accumulated | Total | |||||||||||
| Shares | | Amount | | Capital | | Deficit | | Equity | |||||
As of January 1, 2025 | | $ | | $ | | $ | ( | $ | | |||||
Issuance of stock for vested restricted stock units, net of shares withheld for withholding taxes | | — | ( | — | ( | |||||||||
Stock-based compensation | — | — | | — | | |||||||||
Net loss | — | — | — | ( | ( | |||||||||
As of March 31, 2025 | | | | ( | | |||||||||
Issuance of common stock and pre-funded warrants, net of issuance costs of $ | | | | — | | |||||||||
Issuance of common stock for exercise of warrants | | — | | — | | |||||||||
Issuance of stock for vested restricted stock units, net of shares withheld for withholding taxes | | — | — | — | — | |||||||||
Stock-based compensation | — | — | | — | | |||||||||
Net loss | — | — | — | ( | ( | |||||||||
As of June 30, 2025 | | $ | | $ | | $ | ( | $ | | |||||
As of January 1, 2026 | | $ | | $ | | $ | ( | $ | | |||||
Issuance of common stock and warrants in connection with an underwritten public offering, net of issuance costs of $ | | | | — | | |||||||||
Issuance of common stock under an at the market offering agreement, net of issuance costs of $ | | — | | — | | |||||||||
Issuance of common stock for exercise of warrants | | | — | — | | |||||||||
Issuance of common stock for vested restricted stock units, net of shares withheld for withholding taxes | | — | — | — | — | |||||||||
Stock-based compensation | — | — | | — | | |||||||||
Net loss | — | — | — | ( | ( | |||||||||
As of March 31, 2026 | | | | ( | | |||||||||
Underwritten public offering issuance costs | — | — | ( | — | ( | |||||||||
Issuance of common stock under an at the market offering agreement, net of issuance costs of $ | | — | | — | | |||||||||
Issuance of common stock for exercise of warrants | | | | — | | |||||||||
Issuance of common stock for professional services | | — | | — | | |||||||||
Issuance of common stock for vested restricted stock units | | — | — | — | — | |||||||||
Stock-based compensation | — | — | | — | | |||||||||
Net loss | — | — | — | ( | ( | |||||||||
As of June 30, 2026 | | $ | | $ | | $ | ( | $ | | |||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
5
Table of Contents
MetaVia Inc.
Condensed Consolidated Statements of Cash Flows
(Unaudited - In thousands)
Six Months Ended June 30, | |||||
2026 | 2025 | ||||
Operating activities | |||||
Net loss | $ | ( | $ | ( | |
Adjustments to reconcile net loss to net cash used in operating activities: | |||||
Stock-based compensation |
| |
| | |
Non-cash professional services expenses | | — | |||
Non-cash lease charge (credit) | | ( | |||
Depreciation |
| |
| | |
Gain from change in fair value of warrant liabilities | ( | ( | |||
Change in operating assets and liabilities | |||||
Prepaid expenses and other assets |
| |
| ( | |
Accounts payable |
| ( |
| ( | |
Accrued and other liabilities |
| |
| | |
Net cash used in operating activities |
| ( |
| ( | |
Investing activities | |||||
Purchases of property and equipment |
| — |
| ( | |
Net cash used in investing activities |
| — |
| ( | |
Financing activities | |||||
Proceeds from the issuance of common stock and warrants under an underwritten public offering | | — | |||
Payment of issuance costs in connection with the sale of common stock and warrants under an underwritten public offering | ( | — | |||
Proceeds from the issuance of common stock under an at the market offering agreement | | — | |||
Payment of issuance costs in connection with the sale of common stock under an at the market offering agreement | ( | — | |||
Proceeds from the issuance of common stock and warrants under the securities purchase agreements from a private placement offering | — | | |||
Payment of issuance costs in connection with the sale of common stock and warrants under the securities purchase agreements from a private placement offering | — | ( | |||
Proceeds from exercise of warrants | | | |||
Payment of employee withholding taxes related to shares withheld from vested restricted stock units | — | ( | |||
Net cash provided by financing activities |
| |
| | |
Net increase in cash and cash equivalents |
| |
| | |
Cash and cash equivalents at beginning of period |
| |
| | |
Cash and cash equivalents at end of period | $ | | $ | | |
Supplemental non-cash investing and financing transactions | |||||
Unpaid issuance costs | $ | | $ | | |
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
6
Table of Contents
MetaVia Inc.
Notes to the Condensed Consolidated Financial Statements
(Unaudited)
1.Business, basis of presentation, new accounting standards and summary of significant accounting policies
General
MetaVia Inc. (the “Company”), a Delaware corporation, and its subsidiaries are referred to collectively in these notes to the financial statements of the Company as “MetaVia,” “we,” “our” and “us.” We are a clinical-stage biotechnology company focused primarily on developing novel pharmaceuticals to treat cardiometabolic diseases. We have two programs, vanoglipel and DA-1726, focused primarily on the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and obesity.
While we focus our financial resources and management’s attention on the development of vanoglipel and DA-1726, we also have four legacy therapeutic programs designed to impact a range of indications in viral, neurodegenerative and cardiometabolic diseases which we are not planning to advance development on and have, or continue to consider for, out-licensing and divestiture opportunities. In July 2024, we entered into an exclusive out-license agreement with MThera Pharma Co., LTD. (“MThera”) to provide MThera with the rights to one of our legacy therapeutic programs, NB-01, for the treatment of painful diabetic neuropathy.
Our operations consist principally of performing research and development (“R&D”) activities, which include preclinical development and clinical trials, and raising capital. Our activities are subject to significant risks and uncertainties, including failing to secure additional funding before sustainable revenues and profit from operations are achieved.
Going concern
As reflected in the condensed consolidated financial statements, we had $
We plan to continue to fund our operations through equity offerings, debt financing, the exercise of existing warrants, or other sources, potentially including collaborations, out-licensing and other similar arrangements. However, there can be no assurance that we will be able to obtain any sources of financing on acceptable terms, or at all, or that the warrants issued in previously consummated offerings will be exercised. To the extent that we can raise additional funds by issuing equity securities or in the event our remaining warrants are exercised, our stockholders may experience significant dilution. Any debt financing, if available, may involve restrictive covenants that impact our ability to conduct our business. If we are unable to raise additional capital, we may slow down or stop our ongoing and planned clinical trials until such time as additional capital is raised and this may have a material adverse effect on the Company.
The determination as to whether we can continue as a going concern contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. Our condensed consolidated financial statements have been prepared assuming that we will continue as a going concern and do not include any adjustments that might result from the outcome of this uncertainty. This basis of accounting contemplates the recovery of our assets and the satisfaction of our liabilities in the normal course of business.
A.Basis of presentation
We prepared the condensed consolidated financial statements following the requirements of the United States (“U.S.”) Securities and Exchange Commission (“SEC”) for interim reporting. As permitted under those rules, certain notes or other financial information that are normally required by accounting principles generally accepted in the U.S. (“GAAP”) for complete financial statements can be condensed or omitted. However, except as disclosed herein, there has been no material change in the information disclosed in the notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (“2025 Form 10-K”).
7
Table of Contents
MetaVia Inc.
Notes to the Condensed Consolidated Financial Statements
(Unaudited)
Revenues, expenses, assets, liabilities, and equities can vary during each quarter of the year. Therefore, the results and trends in these condensed consolidated financial statements may not be representative of those for the full year. In our opinion, all adjustments necessary for a fair statement of the condensed consolidated financial statements, which are of a normal and recurring nature, have been made for the interim periods reported. The information included in the condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes included in our 2025 Form 10-K. Certain amounts in the condensed consolidated financial statements and accompanying notes may not add up due to rounding, and all percentages have been calculated using unrounded amounts.
B.New accounting standards
Adoption of new accounting standards
New accounting standards or accounting standards updates were assessed and determined to be either not applicable or did not have a material impact on our consolidated financial statements or processes.
Accounting standards issued but not yet adopted
In November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses to improve financial reporting by requiring that public business entities disclose additional information about specific expense categories in the notes to the consolidated financial statements at interim and annual reporting periods. The amendments in this ASU do not change or remove current expense disclosure requirements; however, the amendments affect where such information appears in the notes to the consolidated financial statements because entities are required to include certain current disclosures in the same tabular format disclosure as the other disaggregation requirements in the amendments. In January 2025, the FASB issued ASU 2025-01, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date. This ASU is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods within annual reporting period beginning after December 15, 2027. Early adoption is permitted. We continue to evaluate the impact of adopting this ASU to our notes to the consolidated financial statements and processes.
Other recently issued accounting standards not yet adopted by us are not expected, upon adoption, to have a material impact on our consolidated financial statements.
C.Estimates and assumptions
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses, and related disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in our condensed consolidated financial statements relate to clinical trial costs and accruals, classification of warrants as derivative liability or equity, and the fair value of stock-based compensation and warrants. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.
D.Significant accounting policies
Our significant accounting policies are described in “Note 1. Business, basis of presentation, new accounting standards and summary of significant accounting policies” in the audited consolidated financial statements and notes thereto for the year ended December 31, 2025, which is included in our 2025 Form 10-K. Except for the following disclosure, there have been no material changes to our significant accounting policies.
Financial Instruments with Characteristics of Both Liabilities and Equity
We account for issued warrants either as a liability or equity in accordance with Accounting Standard Codification (“ASC”) 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity, and ASC 815-40,
8
Table of Contents
MetaVia Inc.
Notes to the Condensed Consolidated Financial Statements
(Unaudited)
Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock. Under ASC 480-10, warrants are considered a liability if they are mandatorily redeemable and they require settlement in cash, other assets, or a variable number of shares. If warrants do not meet liability classification under ASC 480-10, we consider the requirements of ASC 815-40 to determine whether the warrants should be classified as a liability or as equity. Under ASC 815-40, contracts that may require settlement for cash are liabilities, regardless of the probability of the occurrence of the triggering event. Liability-classified warrants are measured at fair value on the issuance date and at the end of each reporting period. Any change in the fair value of the warrants after the issuance date is recorded in other expense, net in the consolidated statements of operations as a gain or loss. If warrants do not require liability classification under ASC 815-40, in order to conclude warrants should be classified as equity, we assess whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or under another applicable GAAP standard. Equity-classified warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date.
2. Prepaid expenses and other current assets
Prepaid expenses and other current assets consist of the following (in thousands):
As of | ||||||
June 30, 2026 | December 31, 2025 | |||||
Insurance | $ | | $ | | ||
Deposits | | | ||||
Deferred equity offering costs | | | ||||
Other prepaid expenses |
| |
| | ||
Total | $ | | $ | | ||
3. Property and equipment, net
Property and equipment, net consist of the following (in thousands):
As of | ||||||
June 30, 2026 | December 31, 2025 | |||||
Office equipment | $ | | $ | | ||
Less accumulated depreciation |
| ( |
| ( | ||
Property and equipment, net | $ | | $ | | ||
We recorded depreciation expense, which was included in G&A operating expenses in the accompanying condensed consolidated statements of operations, of $
4. Current liabilities
Clinical trial accrued liabilities
Clinical trial accrued liabilities was $
9
Table of Contents
MetaVia Inc.
Notes to the Condensed Consolidated Financial Statements
(Unaudited)
Accrued expenses and other current liabilities
Accrued expenses and other current liabilities consist of the following (in thousands):
As of | ||||||
June 30, 2026 | December 31, 2025 | |||||
Employee related costs | $ | | $ | | ||
Professional service fees | | | ||||
Other |
| |
| | ||
Total | $ | | $ | | ||
Warrant liabilities
Changes to our warrant liabilities are summarized as follows (in thousands):
Total | |||
As of January 1, 2025 | $ | | |
( | |||
As of December 31, 2025 | | ||
( | |||
As of June 30, 2026 | $ | | |
Our warrant liabilities relate to the 2022 Series B warrants, which were issued in November 2022. These warrants are considered to be derivative instruments; accordingly, we recorded their estimated fair value as warrant liabilities. We estimated the fair value of these warrants using the trading market price of our common stock due to a cashless exercise provision of these warrants whereby
5.Related party
We entered into a license agreement with Dong-A ST Co., Ltd. (“Dong-A ST”) pursuant to which we received an exclusive global license (except for the territory of the Republic of Korea) for two proprietary compounds for specified indications (the “2022 License Agreement”) upon meeting certain financing milestones. The 2022 License Agreement covers the rights to vanoglipel for treatment of MASH and DA-1726 for treatment of obesity and MASH. The 2022 License Agreement also provides that we may develop vanoglipel for the treatment of type 2 diabetes mellitus.
In connection with the 2022 License Agreement, we entered into a shared services agreement with Dong-A ST (the “Shared Services Agreement”), relating to vanoglipel and DA-1726, pursuant to which Dong-A ST may provide technical support, preclinical development, and clinical trial support services on terms and conditions acceptable to both parties. In addition, the Shared Services Agreement provides that Dong-A ST will manufacture all of our clinical requirements of vanoglipel and DA-1726 under the terms provided in the Shared Services Agreement.
We incurred R&D expenses of $
10
Table of Contents
MetaVia Inc.
Notes to the Condensed Consolidated Financial Statements
(Unaudited)
For additional information on the 2022 License Agreement, the Shared Services Agreement and other agreements with Dong-A ST, refer to “Note 5. Related party” in the audited consolidated financial statements and notes thereto for the year ended December 31, 2025, which is included in our 2025 Form 10-K.
y6. Commitments and contingencies
Contingent payments and license agreements
We have certain contractual contingent payments under various merger or license agreements executed between 2019 and 2020 for our legacy therapeutic programs. Since we have discontinued the clinical development of our legacy therapeutic programs, we believe any contractual payments to be paid by us or to be received by us under these agreements are remote. Therefore, as of June 30, 2026,
Legal proceedings
From time to time, we may be involved in various claims and legal proceedings arising out of our ordinary course of business. We are not currently a party to any claims or legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business and consolidated financial statements. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.
7.Stockholders’ equity
Public offering
In January 2026, we closed on an underwritten public offering and received net proceeds of $
Each pre-funded warrant has an exercise price of $
11
Table of Contents
MetaVia Inc.
Notes to the Condensed Consolidated Financial Statements
(Unaudited)
The following table provides information on the warrants exercised during the three and six months ended June 30, 2026:
Three Months | Six Months | |||
Ended | Ended | |||
Warrant Issuance | June 30, 2026 | June 30, 2026 | ||
January 2026 Pre-funded | | | ||
January 2026 Series C | | | ||
January 2026 Series D | | | ||
Total exercised warrants | | |
At the market offering
In November 2025, we entered into an At The Market Offering Agreement (the “ATM Sales Agreement”) with Ladenburg Thalmann & Co. Inc., as sales agent and/or principal (“Ladenburg”), pursuant to which we could offer and sell, from time to time through or to Ladenburg, shares of our common stock having an aggregate offering price of up to $
Pursuant to the ATM Sales Agreement, Ladenburg may sell the shares by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415(a)(4) of the Securities Act. We are not obligated to make any sales of the shares under the ATM Sales Agreement. The offering of shares pursuant to the ATM Sales Agreement will terminate upon the termination of the ATM Sales Agreement by Ladenburg or us, as permitted therein. We are obligated to pay Ladenburg an aggregate sales agent commission of
In 2026, we sold
Private placement
In May 2025, we closed on a private placement offering with Dong-A ST and Dong-A Socio Holdings Co., Ltd., an affiliate company of Dong-A ST, and received net proceeds of $
Each pre-funded warrant had an exercise price of $
Common stock issued for professional services
In May 2026, we issued
12
Table of Contents
MetaVia Inc.
Notes to the Condensed Consolidated Financial Statements
(Unaudited)
Warrants
The following table summarizes our outstanding warrants:
Shares of Common Stock Issuable | |||||||||
for Outstanding Warrants | |||||||||
As of | Exercise | ||||||||
Warrant Issuance | June 30, 2026 | December 31, 2025 | Price | Expiration Date | |||||
January 2021 | | | $ | July 2026 | |||||
November 2022 Series B (1) | | | $ | December 2027 | |||||
June 2024 Placement Agent | | | $ | July 2026 | |||||
June 2024 Series B (2) | | | $ | September 2029 (latest date) | |||||
January 2026 Series C | | — | $ | January 2031 | |||||
January 2026 Series D (3) | | — | $ | January 2028 | |||||
Total | | | |||||||
Stock-based compensation
Stock-based award plans
Our Amended and Restated 2022 Equity Incentive Plan (the “2022 Plan”) provides for an automatic increase on January 1st of each year for a period of
In June 2026, at our 2026 virtual annual meeting of stockholders, the Company’s stockholders approved the first amendment to the 2022 Plan (the “First Amendment”), which was previously approved by the Board of Directors of the Company. The First Amendment became effective upon stockholder approval, and provides for an increase in the aggregate number of shares of our common stock that may be issued pursuant to the 2022 Plan by
The following table summarizes the outstanding awards issued pursuant to our stock-based award plans and inducement plan as of June 30, 2026 and the remaining shares of common stock available for future issuance:
Remaining shares of | ||||||
Stock | common stock available | |||||
Plan Name | Options | RSUs | for future issuance | |||
2019 Plan | | — | — | |||
2022 Plan | | | | |||
2021 Inducement Plan | — | — | | |||
Total | | | |
13
Table of Contents
MetaVia Inc.
Notes to the Condensed Consolidated Financial Statements
(Unaudited)
Restricted Stock Units
The following table summarizes the status of our outstanding restricted stock units (“RSUs”) and related transactions for the period presented, as well as our vested and deferred release RSUs as of January 1, 2026 and June 30, 2026 (in thousands, except share and per share amounts):
Outstanding | Vested and Deferred Release | |||||||||||||||
Shares of | Average | Shares of | Average | |||||||||||||
Common Stock | Grant Date | Aggregate | Common Stock | Grant Date | Aggregate | |||||||||||
Issuable | Fair Value | Fair | Issuable | Fair Value | Intrinsic | |||||||||||
for RSUs | Price | Value | for RSUs | Price | Value | |||||||||||
As of January 1, 2026 | | $ | | $ | | | $ | | $ | | ||||||
Granted | | | ||||||||||||||
Vested and released | ( | | | |||||||||||||
As of June 30, 2026 | | $ | | $ | | | $ | | $ | | ||||||
Stock-based compensation expense
Stock-based compensation expense was included in operating expenses as follows (in thousands):
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||
2026 | 2025 | 2026 | 2025 | |||||||||
General and administrative | $ | | $ | | $ | | $ | | ||||
Research and development | | | | | ||||||||
Total stock-based compensation | $ | | $ | | $ | | $ | | ||||
For stock-based awards granted under our stock-based award plans as of June 30, 2026, unrecognized stock-based compensation costs totaled $
8.Significant segment expenses and loss before income taxes
We manage and operate as
14
Table of Contents
MetaVia Inc.
Notes to the Condensed Consolidated Financial Statements
(Unaudited)
The following table sets forth the significant segment expenses for our
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||
2026 | 2025 | 2026 | 2025 | |||||||||
Operating expenses | | | | | ||||||||
Research and development | | |||||||||||
Direct costs | ||||||||||||
Vanoglipel | $ | | $ | | $ | | $ | | ||||
DA-1726 | | | | | ||||||||
Other R&D (1) | | | | | ||||||||
Indirect costs | ||||||||||||
Employee compensation and benefits | | | | | ||||||||
Consulting | | | | | ||||||||
Total research and development | | | | | ||||||||
General and administrative | ||||||||||||
Legal and professional fees | | | | | ||||||||
Consulting | | | | | ||||||||
Employee compensation and benefits | | | | | ||||||||
Other G&A (2) | | | | | ||||||||
Total general and administrative | | | | | ||||||||
Total operating expenses |
| |
| | | | ||||||
Loss from operations | ( | ( | ( | ( | ||||||||
Total other income | | | | | ||||||||
Loss before income taxes | $ | ( | $ | ( | $ | ( | $ | ( | ||||
(1)Other R&D expenses include clinical, non-clinical and preclinical services and other R&D expenditures that are not attributable to a single product candidate.
(2)Other G&A expenses include insurance, software license fees, non-income state taxes, lease rental expenses and other G&A expenditures.
9.Income taxes
We do not expect to pay any significant federal or state income taxes as a result of (i) the losses recorded during the three and six months ended June 30, 2026, (ii) additional losses expected for the remainder of 2026, or (iii) net operating loss carry forwards from prior years.
We recorded a full valuation allowance of the net operating losses for the three and six months ended June 30, 2026 and 2025. Accordingly, there were
15
Table of Contents
MetaVia Inc.
Notes to the Condensed Consolidated Financial Statements
(Unaudited)
10.Loss per share of common stock
The following table sets forth the computation of basic and diluted loss per share of common stock (in thousands, except share and per share amounts):
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||
2026 | 2025 | 2026 | 2025 | |||||||||
Numerator: | ||||||||||||
Net loss | $ | ( | $ | ( | $ | ( | $ | ( | ||||
Denominator: | ||||||||||||
Weighted average shares of common stock, basic | ||||||||||||
Effect of dilutive securities | — | — | — | — | ||||||||
Weighted average shares of common stock, diluted | ||||||||||||
Loss per share of common stock, basic and diluted | $ | ( | $ | ( | $ | ( | $ | ( | ||||
For each of the periods presented in the above table, our basic weighted average shares of common stock include any outstanding (i) Series B warrants issued in November 2022, (ii) pre-funded warrants issued in June 2024, May 2025 and January 2026 and (iii) vested RSUs in which their release were deferred.
Since we reported a net loss for the three and six months ended June 30, 2026 and 2025, our potentially dilutive securities are deemed to be anti-dilutive, accordingly, there was no effect of dilutive securities. Therefore, our basic and diluted loss per share of common stock and our basic and diluted weighted average shares of common stock are the same for the three and six months ended June 30, 2026 and 2025.
The following table sets forth the potentially dilutive securities that were not included in the calculation of diluted earnings per share of common stock for three and six months ended June 30, 2026 and 2025:
As of June 30, | ||||
| 2026 | 2025 | ||
Stock options | | | ||
RSUs | | | ||
Warrants | | | ||
11.Fair value of financial instruments
Fair value is a market-based measurement, not an entity specific measurement and is defined as “the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.” Fair value measurements are defined on a three-level hierarchy:
Level 1: | Unadjusted quoted prices for identical assets or liabilities in active markets; |
Level 2: | Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, whether directly or indirectly, for substantially the full term of the asset or liability; and |
Level 3: Unobservable inputs that reflect our own assumptions about the assumptions market participants would use in pricing the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.
16
Table of Contents
MetaVia Inc.
Notes to the Condensed Consolidated Financial Statements
(Unaudited)
The following table sets forth our financial assets and liabilities, subject to fair value measurements on a recurring basis, by level within the fair value hierarchy (in thousands):
As of June 30, 2026 | As of December 31, 2025 | |||||||||||||||||||||||
Description | | Total | | Level 1 | | Level 2 | | Level 3 | | Total | | Level 1 | | Level 2 | | Level 3 | ||||||||
Assets | ||||||||||||||||||||||||
Bank money market funds | $ | | $ | | $ | — | $ | — | $ | | $ | | $ | — | $ | — | ||||||||
Total assets at fair value | $ | | $ | | $ | — | $ | — | $ | | $ | | $ | — | $ | — | ||||||||
Liabilities | ||||||||||||||||||||||||
Warrant liabilities | $ | | $ | — | $ | | $ | — | $ | | $ | — | $ | | $ | — | ||||||||
Total liabilities at fair value | $ | | $ | — | $ | | $ | — | $ | | $ | — | $ | | $ | — | ||||||||
17
Table of Contents
MetaVia Inc.
Form 10-Q
Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the unaudited condensed consolidated financial statements and related notes included elsewhere in this Report and the audited financial statements and related notes included in our 2025 Form 10-K. This discussion contains forward-looking statements based upon current expectations that involve risks and uncertainties. See “Special Note Regarding Forward-Looking Statements.” Our actual results may differ materially from those contained in or implied by any forward-looking statements as a result of various factors, including, but not limited to, the risks and uncertainties described under Part II, Item 1A. Risk Factors, elsewhere in this Report. Certain amounts in the following discussion and analysis may not add up due to rounding, and all percentages have been calculated using unrounded amounts.
Overview
We are a clinical-stage biotechnology company focused primarily on developing novel pharmaceuticals to treat cardiometabolic diseases. We have two ongoing programs focused primarily on the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and obesity.
| ● | Vanoglipel is a novel G-Protein-Coupled Receptor 119 (“GPR119”) agonist with development optionality as a standalone or combination therapy for both MASH and Type 2 Diabetes Mellitus (“T2DM”). Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide 1 (“GLP-1”), glucagon-dependent insulinotropic polypeptide receptor, and peptide YY. These peptides play a further role in glucose metabolism, lipid metabolism and weight loss. Vanoglipel has demonstrated beneficial effects on glucose, lipid profile and liver inflammation, as demonstrated during in-vivo preclinical studies. |
| ● | DA-1726 is a novel oxyntomodulin analog agonist functioning as a GLP-1 receptor (“GLP1R”) and glucagon receptor (“GCGR”) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously. With the activation of the dual agonist, weight loss may be achieved by GLP1R reducing appetite while GCGR increases energy expenditure. |
While we primarily focus our financial resources and management’s attention on the development of vanoglipel and DA-1726, we also have four legacy therapeutic programs designed to impact a range of indications in viral, neurodegenerative and cardiometabolic diseases on which we are not planning to advance development and have, or continue to consider for, out-licensing and divestiture opportunities.
Our operations have consisted principally of performing research and development (“R&D”) activities, which includes preclinical developments and clinical trials, and raising capital. Our activities are subject to significant risks and uncertainties, such as failing to secure additional funding before sustainable revenues and profit from operations are achieved. For more information on our business and product candidates, see “Part I, Item 1. Business” in our 2025 Form 10-K.
Vanoglipel
We initiated a Phase 2a clinical trial in 2023 with the goal of establishing the mechanism of action and efficacy of vanoglipel in the treatment of MASH and to evaluate trends for T2DM. This is the first-in-human MASH clinical trial for vanoglipel. We are expecting to finalize the Clinical Study Report of the Phase 2a clinical trial in the fourth quarter of 2026. We are also currently working to schedule an end-of-Phase 2 meeting with the Food and Drug Administration to discuss the clinical development pathway for the vanoglipel combination therapy.
For additional information on vanoglipel, including an overview of the top-line 16-week results from the two-part Phase 2a clinical trial, see “Part I, Item 1. Business, Our Pipeline, vanoglipel (DA-1241) Treatment of MASH” in our 2025 Form 10-K and our Current Reports on Form 8-Ks dated May 18, 2026 and June 8, 2026.
DA-1726
We initiated a Phase 1 clinical trial in 2024 with the goal of establishing the safety and tolerability of DA-1726 while exploring the mechanism of action and efficacy of DA-1726 in the treatment of obesity. This is the first-in-human clinical trial for DA-
18
Table of Contents
MetaVia Inc.
Form 10-Q
1726. We started Part 3a and Part 3b of the Phase 1 clinical trial in April 2026. Part 3a will be a one-step titration with 16 mg for four weeks and 48 mg for 12 weeks. Part 3b will be a two-step titration with 16 mg for four weeks, 32 mg for four weeks and 64 mg for eight weeks. These titration studies are to see if the graduated increase in dose can remove any moderate adverse effects from the 48 mg dose level and to seek DA-1726 at a higher dose level of 64 mg. We expect dose-dependent exploratory weight loss and other early signals in the exploratory endpoints with potential for best-in-class safety and tolerability. The data readout for both Part 3a and Part 3b is planned for the fourth quarter of 2026.
For additional information on DA-1726, see “Part I, Item 1. Business, Our Pipeline, DA-1726 Treatment of Obesity” in our 2025 Form 10-K and our Current Reports on Form 8-Ks dated January 5, 2026, March 18, 2026, April 10, 2026, May 11, 2026, May 18, 2026, May 27, 2026, June 8, 2026 and July 9, 2026.
Recent developments
| ● | April 2026: Dosed the first patient in the Phase 1, Part 3 clinical trial for DA-1726 in obese, otherwise healthy adults using one-step titration to 48 mg and two-step titration to 64 mg to safely achieve higher target doses and optimize tolerability. |
| ● | May 2026: Presented additional data from the 48 mg Phase 1 clinical trial of DA-1726 at the European Association for the Study of the Liver Congress 2026 (EASL 2026), which was held May 27-30 in Barcelona, Spain, demonstrating up to 9.1% mean body weight reduction without evidence of plateau and exploratory improvements in liver-related biomarkers, supporting the potential of DA-1726 in obesity and MASH. |
| ● | June 2026: Presented new late-breaking data at the American Diabetes Association’s (ADA) 2026 Scientific Sessions, which was held in New Orleans, Louisiana, United States, supporting DA-1726's differentiated obesity profile and demonstrating the combination potential of vanoglipel with resmetirom in MASH and metformin in type 2 diabetes. |
| ● | July 2026: Announced the completion of dose titration in the 16-week, Phase 1 Part 3 study of DA-1726, with all active patients successfully reaching the highest planned dose levels of 48 mg and 64 mg. |
Key operating information
Our key operating information is described in “Key operating information” within “Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 2025 Form 10-K. There have been no material changes to our key operating information.
19
Table of Contents
MetaVia Inc.
Form 10-Q
Results of operations
Three months ended June 30, 2026 compared to three months ended June 30, 2025
The following table summarizes our results of operations (in thousands, except share and per share amounts):
Three Months Ended June 30, | ||||||
| 2026 | 2025 | ||||
Operating expenses | ||||||
Research and development | $ | 3,478 | $ | 2,320 | ||
General and administrative | 1,907 | 1,981 | ||||
Total operating expenses |
| 5,385 |
| 4,301 | ||
Loss from operations |
| (5,385) |
| (4,301) | ||
Other income (expense) | ||||||
(Loss) gain from change in fair value of warrant liabilities | (4) | 160 | ||||
Interest income, net | 73 | 146 | ||||
Total other income | 69 | 306 | ||||
Loss before income taxes | (5,316) | (3,995) | ||||
Provision for income taxes | — | — | ||||
Net loss | $ | (5,316) | $ | (3,995) | ||
Loss per share of common stock, basic and diluted | $ | (0.90) | $ | (2.87) | ||
Weighted average shares of common stock, basic and diluted |
| 5,931,875 |
| 1,389,753 | ||
Total operating expenses and loss from operations
Our total operating expenses and loss from operations for the three months ended June 30, 2026 were $5.4 million, an increase of approximately $1.1 million, or 25.2%, compared to the corresponding period in 2025. This increase was mainly attributable to higher R&D expenses for the three months ended June 30, 2026, partially offset by lower general and administrative (“G&A”) expenses. Our R&D expenses were $3.5 million for the three months ended June 30, 2026, an increase of $1.2 million, or 49.9%, compared to the corresponding period in 2025. Our G&A expenses were $1.9 million for the three months ended June 30, 2026, a decrease of approximately $0.1 million, or 3.7%, compared to the corresponding period in 2025.
The following table summarizes our R&D expenses for the three months ended June 30, 2026 and 2025 (in thousands):
Three Months Ended June 30, | ||||||
| 2026 | 2025 | ||||
Direct costs | ||||||
Vanoglipel | $ | 235 | $ | 277 | ||
DA-1726 | 2,717 | 1,529 | ||||
Other R&D | 40 | 30 | ||||
Indirect costs | ||||||
Employee compensation and benefits | 439 | 441 | ||||
Consulting | 47 | 43 | ||||
Total research and development | $ | 3,478 | $ | 2,320 | ||
The $1.2 million increase in R&D expenses reflects increased R&D activities related to the Phase 1 clinical trial for DA-1726 during the three months ended June 30, 2026 as compared to the corresponding period in 2025. Specifically, the increase in R&D expenses was mainly attributable to higher direct R&D expenses related to DA-1726 product development. Included in direct R&D costs were expenses totaling $0.2 million and $1.3 million for the three months ended June 30, 2026 and 2025, respectively, related to investigational drug manufacturing, non-clinical and preclinical costs incurred under the Shared Services Agreement with Dong-A ST (related party).
The approximately $0.1 million decrease in G&A expenses was primarily attributable to lower legal and professional fees.
20
Table of Contents
MetaVia Inc.
Form 10-Q
Total other income
Our total other income for the three months ended June 30, 2026 was $0.1 million, a decrease of $0.2 million, or 77.5%, compared to the corresponding period in 2025. This decrease was attributable to an approximately $0.2 million negative impact from the change in fair value of warrant liabilities due to the impact of our common stock’s decline in stock price and approximately $0.1 million in lower interest income, net, due to lower balances of cash and cash equivalents and lower interest rates.
Provision for income taxes
Our provision for income taxes and effective tax rate for the three months ended June 30, 2026 and 2025 were zero as we have recorded a full valuation allowance for the income tax benefits attributable to our pre-tax losses.
Net loss
For the three months ended June 30, 2026, we had a net loss of $5.3 million, or $0.90 per share of basic and diluted common stock, compared to a net loss of $4.0 million, or $2.87 per share of basic and diluted common stock for the corresponding period in 2025, primarily due to the factors described above.
Six months ended June 30, 2026 compared to six months ended June 30, 2025
The following table summarizes our results of operations (in thousands, except share and per share amounts):
Six Months Ended June 30, | ||||||
| 2026 | 2025 | ||||
Operating expenses | ||||||
Research and development | $ | 5,579 | $ | 4,647 | ||
General and administrative | 3,831 | 3,540 | ||||
Total operating expenses |
| 9,410 |
| 8,187 | ||
Loss from operations |
| (9,410) |
| (8,187) | ||
Other income | ||||||
Gain from change in fair value of warrant liabilities | 113 | 247 | ||||
Interest income, net | 158 | 274 | ||||
Total other income | 271 | 521 | ||||
Loss before income taxes | (9,139) | (7,666) | ||||
Provision for income taxes | — | — | ||||
Net loss | $ | (9,139) | $ | (7,666) | ||
Loss per share of common stock, basic and diluted | $ | (1.69) | $ | (6.59) | ||
Weighted average shares of common stock, basic and diluted |
| 5,398,683 |
| 1,162,692 | ||
Total operating expenses and loss from operations
Our total operating expenses and loss from operations for the six months ended June 30, 2026 were $9.4 million, an increase of approximately $1.2 million, or 14.9%, compared to the corresponding period in 2025. This increase was attributable to higher R&D and G&A expenses for the six months ended June 30, 2026. Our R&D expenses were $5.6 million for the six months ended June 30, 2026, an increase of $0.9 million, or 20.1%, compared to the corresponding period in 2025. Our G&A expenses were $3.8 million for the six months ended June 30, 2026, an increase of approximately $0.3 million, or 8.2%, compared to the corresponding period in 2025.
21
Table of Contents
MetaVia Inc.
Form 10-Q
The following table summarizes our R&D expenses for the six months ended June 30, 2026 and 2025 (in thousands):
Six Months Ended June 30, | ||||||
| 2026 | 2025 | ||||
Direct costs | ||||||
Vanoglipel | $ | 402 | $ | 568 | ||
DA-1726 | 4,164 | 3,008 | ||||
Other R&D | 53 | 55 | ||||
Indirect costs | ||||||
Employee compensation and benefits | 880 | 950 | ||||
Consulting | 80 | 66 | ||||
Total research and development | $ | 5,579 | $ | 4,647 | ||
The $0.9 million increase in R&D expenses reflects increased R&D activities related to the Phase 1 clinical trial for DA-1726 during the six months ended June 30, 2026 as compared to the corresponding period in 2025. Specifically, the increase in R&D expenses was primarily attributable to $1.2 million in higher direct R&D expenses related to DA-1726 product development, partially offset by (i) $0.2 million in lower direct R&D expenses related to vanoglipel product development and (ii) $0.1 million in lower indirect employee compensation and benefits costs. Included in direct R&D costs were expenses totaling $0.9 million and $2.4 million for the six months ended June 30, 2026 and 2025, respectively, related to investigational drug manufacturing, non-clinical and preclinical costs incurred under the Shared Services Agreement with Dong-A ST (related party).
The $0.3 million increase in G&A expenses was primarily attributable to (i) $0.1 million in higher consulting expenditures, (ii) approximately $0.1 million in higher employee compensation and benefits costs, and (iii) $0.1 million in higher other G&A expenses, which was primarily related to higher franchise tax expenses.
Total other income
Our total other income for the six months ended June 30, 2026 was $0.3 million, a decrease of approximately $0.3 million, or 48.0%, compared to the corresponding period in 2025. This decrease was attributable to (i) approximately $0.1 million in lower gain from change in fair value of warrant liabilities due to the impact of our common stock’s decline in stock price and (ii) approximately $0.1 million in lower interest income, net, due to lower balances of cash and cash equivalents and lower interest rates.
Provision for income taxes
Our provision for income taxes and effective tax rate for the six months ended June 30, 2026 and 2025 were zero as we have recorded a full valuation allowance for the income tax benefits attributable to our pre-tax losses.
Net loss
For the six months ended June 30, 2026, we had a net loss of $9.1 million, or $1.69 per share of basic and diluted common stock, compared to a net loss of $7.7 million, or $6.59 per share of basic and diluted common stock for the corresponding period in 2025, primarily due to the factors described above.
Going concern
As reflected in the unaudited condensed consolidated financial statements, we had $12.6 million in cash and cash equivalents as of June 30, 2026. We have experienced net losses and negative cash flows from operating activities since our inception and had an accumulated deficit of $158.0 million as of June 30, 2026. We have incurred a net loss of $9.1 million and net cash used in operating activities of $8.0 million for the six months ended June 30, 2026. Due in large part to the ongoing clinical trials, we expect to continue to incur net losses and negative cash flows from operating activities for the foreseeable future. These conditions raise substantial doubt about our ability to continue as a going concern within one year from the issuance of these unaudited condensed consolidated financial statements.
We plan to continue to fund our operations from equity offerings, debt financing, exercise of existing warrants, or other sources,
22
Table of Contents
MetaVia Inc.
Form 10-Q
potentially including collaborations, out-licensing and other similar arrangements. However, there can be no assurance that we will be able to obtain any sources of financing on acceptable terms, or at all, or that the warrants issued in previously consummated offerings will be exercised. To the extent that we can raise additional funds by issuing equity securities or in the event our remaining warrants are exercised, our stockholders may experience significant dilution. Any debt financing, if available, may involve restrictive covenants that impact our ability to conduct our business. If we are unable to raise additional capital, we may slow down or stop our ongoing and planned clinical trials until such time as additional capital is raised and this may have a material adverse effect on us.
The determination as to whether we can continue as a going concern contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. Our unaudited condensed consolidated financial statements have been prepared assuming that we will continue as a going concern and do not include any adjustments that might result from the outcome of this uncertainty. This basis of accounting contemplates the recovery of our assets and the satisfaction of our liabilities in the normal course of business.
Liquidity and capital resources
Our primary use of cash is to fund our R&D activities. We have funded our operations primarily through public offerings of our common stock and private placements of equity and convertible securities. As of June 30, 2026, we had cash and cash equivalents totaling $12.6 million. We maintain cash and cash equivalents at a financial institution that at times may exceed the Federal Deposit Insurance Corporation insured limits of $0.25 million per bank. To date, we have not experienced any losses related to these funds. Our cash equivalents consist principally of bank money market accounts and these securities are carried at cost, which approximates market value.
Public offering
In January 2026, we closed on an underwritten public offering and received net proceeds of $7.1 million, pursuant to which we issued and sold, (i) 1,006,870 Class A Units, with each Class A Unit consisting of (A) one share of common stock, (B) 1.5 Series C Common Warrants to purchase 1.5 shares of common stock, and (C) 1.5 Series D Common Warrants to purchase 1.5 shares of common stock, at a price of $3.10 per Class A Unit, and (ii) 1,998,704 Class B Units, with each Class B Unit consisting of (A) one pre-funded warrant to purchase one share of common stock, (B) 1.5 Series C Common Warrants to purchase 1.5 shares of common stock, and (C) 1.5 Series D Common Warrants to purchase 1.5 shares of common stock, at a purchase price of $3.099 per Class B Unit.
Each pre-funded warrant has an exercise price of $0.001 per share and is immediately exercisable and will expire when exercised in full. Each Series C Common Warrant and Series D Common Warrant has an exercise price of $3.10 per whole share of common stock, subject to certain adjustments, are immediately exercisable, and will expire on January 16, 2031 and January 16, 2028, respectively. Under the Series C Common Warrant and the Series D Common Warrant, we may not affect the exercise of any such warrants, and a holder will not be entitled to exercise any portion of any such warrants, which, upon giving effect to such exercise, would cause the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates) to exceed the beneficial ownership limitation contained therein. The Series D Common Warrants are callable at our option following the release of a positive data readout for our Phase 1, Part 3 clinical trial for DA-1726 via a widely disseminated press release, subject to the satisfaction of certain conditions. The Series C Common Warrants and Series D Common Warrants are fixed priced and do not contain any variable pricing features or alternative exercise provisions.
The following table provides information on the warrants exercised during the three and six months ended June 30, 2026:
Three Months | Six Months | |||
Ended | Ended | |||
Warrant Issuance | June 30, 2026 | June 30, 2026 | ||
January 2026 Pre-funded | 367,740 | 1,998,704 | ||
January 2026 Series C | 30,039 | 30,039 | ||
January 2026 Series D | 749,539 | 749,539 | ||
Total | 1,147,318 | 2,778,282 |
23
Table of Contents
MetaVia Inc.
Form 10-Q
At the market offering
In November 2025, we entered into an At The Market Offering Agreement (the “ATM Sales Agreement”) with Ladenburg Thalmann & Co. Inc., as sales agent and/or principal (“Ladenburg”), pursuant to which we could offer and sell, from time to time through or to Ladenburg, shares of our common stock having an aggregate offering price of up to $2.3 million (the “ATM Program”) through June 30, 2026. The offer and sale of the shares of common stock pursuant to the ATM Program through June 30, 2026 was made pursuant to a shelf registration statement on Form S-3 and the related prospectus (File No. 333-278646) filed with the SEC on April 12, 2024, and declared effective by the SEC on April 23, 2024, as supplemented by a prospectus supplement filed with the SEC on November 6, 2025 pursuant to Rule 424(b) under the Securities Act.
Pursuant to the ATM Sales Agreement, Ladenburg may sell the shares by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415(a)(4) of the Securities Act. We are not obligated to make any sales of the shares under the ATM Sales Agreement. The offering of shares pursuant to the ATM Sales Agreement will terminate upon the termination of the ATM Sales Agreement by Ladenburg or us, as permitted therein. We are obligated to pay Ladenburg an aggregate sales agent commission of 3.0% of the gross sales price of the shares sold pursuant to the ATM Sales Agreement. We will also reimburse Ladenburg for certain specified expenses in connection with entering into the ATM Sales Agreement, which contains customary representations and warranties and conditions to the placements of the shares pursuant thereto.
In 2026, we sold 422,919 shares of common stock under the ATM Program and received net proceeds of $0.7 million, net of sales agent commission and related offering expenses. As of June 30, 2026, we had $0.2 million remaining under the ATM Program in which we may offer and sell shares of our common stock. On July 2, 2026, we increased the size of the ATM Program to allow the offer and sale of shares of our common stock having an aggregate offering price of up to $4.0 million.
Cash flows
The principal use of cash in operating activities is to fund our current expenditures in support of our R&D activities. Financing activities currently represent the principal source of our cash flow.
The following table reflects the major categories of cash flows (in thousands).
Six Months Ended June 30, | ||||||
| 2026 | 2025 | ||||
Net cash used in operating activities | $ | (8,020) | $ | (7,886) | ||
Net cash used in investing activities | — | (2) | ||||
Net cash provided by financing activities |
| 10,376 | 9,460 | |||
Net increase in cash and cash equivalents | $ | 2,356 | $ | 1,572 | ||
Net cash used in operating activities for the six months ended June 30, 2026 was approximately $8.0 million and primarily attributable to net loss of $9.1 million, partially offset by changes in operating assets and liabilities of $0.8 million and non-cash charges totaling $0.3 million, which was primarily related to stock-based compensation, non-cash professional services expenses and change in fair value of warrant liabilities. Net cash used in operating activities for the six months ended June 30, 2025 was $7.9 million and primarily attributable to net loss of $7.7 million and net cash used in changes in operating assets and liabilities of $0.2 million.
There were no cash flows used in or provided by investing activities for the six months ended June 30, 2026 while cash used in investing activities for the six months ended June 30, 2025 was minimal and related to the purchase of property and equipment.
Net cash provided by financing activities for the six months ended June 30, 2026 was $10.4 million and primarily attributable to gross proceeds of (i) $9.3 million from an underwritten public offering in January 2026, (ii) $0.9 million from the sale of common stock under the ATM Sales Agreement and (iii) $2.4 million from exercise of warrants. Partially offsetting these gross proceeds was an aggregate payment of $2.3 million in issuance costs in connection with the sale of common stock and warrants under an underwritten public offering and under an at the market offering agreement. Net cash provided by financing activities for the six months ended June 30, 2025 was $9.5 million and primarily attributable to gross proceeds of $10.0 million from the
24
Table of Contents
MetaVia Inc.
Form 10-Q
May 2025 private placement offering, partially offset by the payment of $0.5 million of issuance costs in connection with the May 2025 private placement offering.
For additional details, see the unaudited condensed consolidated statements of cash flows in the unaudited condensed consolidated financial statements included elsewhere in this Report.
Critical accounting estimates
Our unaudited condensed consolidated financial statements included in this Report have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses, and related disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in our unaudited condensed consolidated financial statements relate to accrued expenses and the fair value of stock-based compensation and warrants. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.
There have been no material changes to our critical accounting estimates and judgments since December 31, 2025. Refer to our 2025 Form 10-K for a complete discussion of our critical accounting estimates and judgments.
Recent accounting pronouncements
Information regarding (i) adoption of new accounting standards and (ii) accounting standards issued but not yet adopted is included in “Note 1. Business, basis of presentation, new accounting standards and summary of significant accounting policies” to the unaudited condensed consolidated financial statements included in this Report.
Item 3.Quantitative and Qualitative Disclosures about Market Risk
Not applicable.
Item 4.Controls and Procedures
Evaluation of disclosure controls and procedures
As required by Rules 13a-15(b) and 15d-15(b) under Section 21E of the Exchange Act, our management, with the participation of our principal executive officer (“PEO”) and principal financial officer (“PFO”), evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this Report. Based upon that evaluation, our PEO and PFO concluded that our disclosure controls and procedures were effective as of the end of the period covered by this Report.
Inherent limitations of disclosure controls and procedures
Our management, including our PEO and PFO, does not expect that our disclosure controls and procedures will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate.
25
Table of Contents
MetaVia Inc.
Form 10-Q
Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.
Changes in internal control over financial reporting
There have been no changes in our internal control over financial reporting during the quarter ended June 30, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Part II - Other Information
Item 1.Legal Proceedings
From time to time, we may be involved in various claims and legal proceedings arising out of our ordinary course of business. We are not currently a party to any claims or legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business and unaudited condensed consolidated financial statements. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.
Item 1A.Risk Factors
Our business, financial condition and operating results can be affected by a number of factors, whether currently known or unknown, including but not limited to those described under the heading “Risk Factors” in Part I, Item 1A of the 2025 Form 10-K, any one or more of which could, directly or indirectly, cause our actual financial condition and operating results to vary materially from past, or from anticipated future, financial condition and operating results. Any of these factors, in whole or in part, could materially and adversely affect our business, financial condition, operating results and stock price. There have been no material changes to our risk factors since the 2025 Form 10-K.
Item 2.Unregistered Sales of Equity Securities and Use of Proceeds
On May 20, 2026, we issued 50,000 shares of common stock, based on a closing price of $2.89 per share on the date of issuance, to a vendor for business advisory services provided by the vendor. Based in part on the representations made by the vendor, the offer and sale of the shares of common stock was made in reliance upon the exemption from registration contained in Section 4(a)(2) of the Securities Act and/or Regulation D promulgated thereunder, as a transaction by an issuer not involving a public offering.
Item 3.Defaults Upon Senior Securities
None.
Item 4.Mine Safety Disclosures
Not applicable.
Item 5.Other Information
Item 6.Exhibits
Exhibit Number | | Description of Document |
3.1 | Third Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed with the SEC on August 10, 2016). |
26
Table of Contents
MetaVia Inc.
Form 10-Q
3.2 | Certificate of Amendment (Reverse Stock Split) to the Third Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed with the SEC on December 31, 2019). | |
3.3 | Certificate of Amendment (Name Change) to the Third Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K, filed with the SEC on December 31, 2019). | |
3.4 | Certificate of Amendment (Reverse Stock Split) to the Third Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed with the SEC on September 12, 2022). | |
3.5 | Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed with the SEC on December 19, 2023). | |
3.6 | Certificate of Amendment (Name Change) to the Third Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed with the SEC on November 18, 2024). | |
3.7 | Certificate of Amendment (Reverse Stock Split) to the Third Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed with the SEC on December 2, 2025). | |
3.8 | Fourth Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K, filed with the SEC on November 18, 2024). | |
10.1#* | Amended and Restated Non-Employee Director Compensation Policy, dated May 7, 2024, as amended November 29, 2024 and June 8, 2026. | |
10.2 | First Amendment to the Registrant’s Amended and Restated 2022 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed with the SEC on June 8, 2026). | |
31.1* | Certification of Principal Executive Officer Pursuant to Exchange Act Rule 13a-14(a) or 15d-14(a), as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |
31.2* | Certification of Principal Financial Officer Pursuant to Exchange Act Rule 13a-14(a) or 15d-14(a), as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |
32.1** | Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |
32.2** | Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |
101.INS* | Inline XBRL Instance Document | |
101.SCH* | Inline XBRL Taxonomy Extension Schema Document | |
101.CAL* | Inline XBRL Taxonomy Extension Calculation Linkbase Document | |
101.DEF* | Inline XBRL Taxonomy Extension Definition Linkbase Document | |
101.LAB* | Inline XBRL Taxonomy Extension Label Linkbase Document | |
101.PRE* | Inline XBRL Taxonomy Extension Presentation Linkbase Document | |
104* | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) |
#Indicates management contract or compensatory plan.
*Filed herewith
**Furnished herewith
27
Table of Contents
MetaVia Inc.
Form 10-Q
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized, on August 6, 2026.
METAVIA INC. | |||
/s/ Hyung Heon Kim | |||
Hyung Heon Kim | |||
President and Chief Executive Officer | |||
/s/ Marshall H. Woodworth | |||
Marshall H. Woodworth | |||
Chief Financial Officer | |||
28